On 12 Nov 2026 ResMed closed at $238.89, +0.3% this year; market cap $34.26bn, P/E 21.5.
Health Care · Health Care Equipment · NYSE · United States
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
| Market cap | $34.26bn |
| P/E (trailing) | 21.5 |
| EPS (TTM) | $11.11 |
| Beta | 0.76 |
| Dividend | $2.64 |
| Dividend yield | 1.11% |
| Ex-dividend date | 12 Nov 2026 |
| Latest report | 29 Oct 2026 |
| Next earnings | 28 Jan 2027 |
| YTD | +0.3% |
| 1Y | -4.3% |
| 3Y | +19.9% |
| 5Y | -0.4% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | $5.65bn | $1.52bn | $1.65bn |
| 2025 | $5.15bn | $1.40bn | $1.66bn |
| 2024 | $4.69bn | $1.02bn | $1.29bn |
| 2023 | $4.22bn | $897.56m | $559.30m |
| 2022 | $3.58bn | $779.44m | $195.11m |
We publish no single base value for ResMed. Our valuation methods put it between $279.84 and $412.13 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.